A clinical trial to compare the effects of ranitidine, pantoprazole, and sucralfate on the prevention of gastrointestinal bleeding and ventilator-associated pneumonia in children under mechanical ventilation.

开始日期2020-02-20

申办/合作机构

Mashhad University of Medical Sciences

KCT0005871

/ Terminated临床4期IIT

Influence of pretreatment with ranitidine bismuth citrate on the cure rates of Helicobacter pylori eradication

开始日期2019-06-03

申办/合作机构

Kyung Hee University Hospital at Gangdong

EUCTR2017-003535-11-NL

/ Unknown status临床4期IIT

The added value of the H2-antagonist ranitidine in premedication regimens during paclitaxel treatment - RANISTOP

开始日期2018-09-21

申办/合作机构

Erasmus MC

[+1]

100 项与雷尼替丁枸橼酸铋相关的临床结果

登录后查看更多信息

100 项与雷尼替丁枸橼酸铋相关的转化医学

登录后查看更多信息

100 项与雷尼替丁枸橼酸铋相关的专利（医药）

登录后查看更多信息

10,061

项与雷尼替丁枸橼酸铋相关的文献（医药）

2025-09-01·RADIATION PHYSICS AND CHEMISTRY

Exploring software tools for comparative evaluation of radiation attenuation parameters in various drugs across gamma, electron, neutron, and ion radiations

作者: Kotb, N. A. ; Abdelmonem, A. M. ; El-Kawy, O. A.

This study investigates the radiation attenuation parameters for some commonly used pharmaceutical drugs like diazepam, ibutilide, levofloxacin, ibuprofen, ranitidine, and celecoxib, which are crucial for medical applications.Through computational analyses employing advanced software tools such as Phy-X/PSD, Py-MLBUF, GRASP, SRIM Monte Carlo, and ESTAR NIST, the mass attenuation coefficient, linear attenuation coefficient, half-value layer, mean free path, effective at. number, and effective electron d. were determined across a broad energy spectrum.Addnl., ionizing radiation interactions with gamma rays, ion particles (H⁺, He²⁺, Bi³⁺, Ti⁴⁺, Gd³⁺, and In³⁺), and electrons were examined, along with fast neutron removal cross-section (FNRCS) and macroscopic effective removal cross-section (MRCS).The results offer valuable insights applicable to radiation physics, pharmacol., and medical physics, enhancing understanding of radiation-drug interactions essential for medical diagnostics and therapies.

2025-08-01·Current Drug Safety

Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature

Article

作者: S, Nirenjen ; T., Tamilanban ; Manavalan, Mohankumar ; Raja, Sangeetha ; Subramanian, Arunkumar ; Haitharali, Rajamohamed ; Gnanasekaran, Sabariakilesh ; Dhanasekaran, Sivaraman

Background::

Stevens-Johnson Syndrome (SJS) is an infrequent yet severe mucocutaneous reaction that involves less than 10% of the Body Surface Area (BSA). It is predominantly induced by certain medications, including anticonvulsants (e.g., Lamotrigine, Carbamazepine, Phenytoin, Phenobarbitone), Allopurinol at doses above 100 mg per day, and sulphonamides (e.g., Cotrimoxazole, Sulfasalazine). Genetic predispositions, particularly the presence of the HLA-B*1502 allele, significantly increase the risk of developing SJS. This case report discusses a unique presentation of SJS in a young female patient, emphasizing the critical need for genetic screening and careful monitoring when prescribing Carbamazepine, especially in populations at higher genetic risk.

Case Presentation::

A 19-year-old female patient, who had been on Phenytoin and Sodium Valproate for epilepsy management over the past year, was newly prescribed Carbamazepine. Within a week of initiating Carbamazepine, the patient experienced a seizure, followed by the sudden onset of fever, painful sores, and blisters covering the upper body, along with mucous discharge from both eyes. These symptoms rapidly worsened. Based on clinical presentations and the extent of epidermal detachment, the patient was diagnosed with SJS. The severity and mortality risks were assessed using the SCORTEN score. Therapeutic interventions included intravenous Ranitidine, Ondansetron, Paracetamol, Midazolam, Levetiracetam, and Dexamethasone, along with oral Fluconazole, Chlorpheniramine tablets, and Ciprofloxacin eye drops. The patient showed significant improvement and was discharged after fourteen days with followup advice.

Conclusion::

This case underscores the critical importance of performing genetic testing for the HLA-B*1502 allele and conducting baseline blood tests before initiating Carbamazepine therapy. Such precautionary measures can significantly mitigate the risk of severe adverse reactions like SJS. This report adds to the scientific literature by highlighting the potential dangers associated with anticonvulsant therapies and the necessity for personalized medicine approaches in preventing life-threatening conditions. The main takeaway is the pivotal role of genetic screening and vigilant monitoring in the management of patients requiring anticonvulsant medications to prevent serious adverse reactions.

2025-07-01·SEPARATION AND PURIFICATION TECHNOLOGY

A hybrid LMO MOF catalytic membrane with PMS activation for efficient degradation of pharmaceutical micropollutants and nanoplastics removal

作者: Sharmin, Afia ; Bhuiyan, Muhammed A. ; Pramanik, Biplob Kumar

In this study, a novel hybrid CoFe layered metal oxide (CoFeLMO) membrane was developed by integrating metal-organic framework (MOF) MIL(100)Fe and polyethylene glycol (PEG), designed specifically for peroxymonosulfate (PMS)-based advanced oxidation processes.The uniqueness of this research lies in the innovative incorporation of LMO, MOF, and PEG nanosheets onto a polyethersulfone (PES) substrate, creating a highly efficient catalytic membrane for the simultaneous removal of pharmaceutical micropollutants and nanoplastics (NPs).Among various configurations, the LMO-MOF-PEG membrane, with 20% MOF (0.025 M) and 0.5 g of PEG, demonstrated superior performance, achieving remarkable removal efficiencies of 99.5% for ranitidine and 98.5% for NPs.This membrane also exhibited outstanding operational efficiency, achieving a flux of 1600 L/m2/h/bar at a low PMS concentration of 0.2 mM.The degradation of ranitidine was driven by both reactive species (SO^•-₄, ^•OH and O^•-₂) and non-reactive species (singlet ¹O₂), with SO^•-₄ playing a dominant role.Post-activation anal. revealed the presence of Co²⁺ and Fe²⁺ in both + II and + III oxidation, indicating the active participation of metal plots in the degradation process and confirming the membrane's reusability.The membrane demonstrated exceptional durability, maintaining a flux recovery ratio of 97-99% across 10 filtration cycles, even under harsh chem. conditions and across a wide pH range (2-12).Furthermore, Co leaching was minimal (2-21μg/L) over a broad pH spectrum, even after 15 days of immersion in water.

项与雷尼替丁枸橼酸铋相关的新闻（医药）

2023-01-15

·蒲公英Ouryao

3000个品种拟终止挂网、公示期截止1月19日！

转自：宁夏公共资源中心编辑：wangxinglai20042023年01月13日，宁夏公共资源中心发布了《一年内无实际入库交易、产品资质到期的药品取消中标（挂网）资格通知》，共涉及一年内无实际入库交易品种2065个、资质到期品种1054个，公示期2023年1月13日至1月19日。通知原文各相关企业：为进一步做好药品阳光挂网采购工作，确保临床需求药品有效供应，根据《宁夏回族自治区药品阳光挂网实施细则（试行）》的通知（宁医保发［2021]182号）文件要求，对宁夏医药采购平台中一年内无实际入库交易、产品资质到期的药品取消中标（挂网）资格（数据统计时间 2022年1月1日至 12月 31日）。公示期：2023年1月13日至1月19日。公示期内如有异议，请企业登录“宁夏医药采购平台”进入主页“综合服务”，点击“申投诉管理”模块递交申投诉资料，逾期不予受理。一年内无实际入库交易品种2065个：氨基己酸注射液、注射用维布妥昔单抗、依洛硫酸酯酶α注射液、盐酸阿莫罗芬乳膏、婴儿保肺散、培塞利珠单抗注射液、聚普瑞锌颗粒、当归益血口服液、聚普瑞锌颗粒、呋喃唑酮片、吲哚美辛片、注射用醋酸卡泊芬净、注射用醋酸卡泊芬净、磺达肝癸钠注射液、他克莫司软膏、注射用醋酸卡泊芬净、中长链脂肪乳/氨基酸(16)/葡萄糖(16%)注射液、卡贝缩宫素注射液、腹膜透析液(乳酸盐-G1.5%) 、明目地黄丸(浓缩丸) 、注射用特利加压素、香砂六君丸(浓缩丸) 、心宝丸、糠酸氟替卡松维兰特罗吸入粉雾剂(Ⅱ) 、安立生坦片、拉西地平片、枸橼酸铋雷尼替丁胶囊、人粒细胞刺激因子注射液、注射用头孢他啶、注射用丁二磺酸腺苷蛋氨酸、复方儿茶胶囊、复方龙胆碳酸氢钠片、枸橼酸铋钾口服溶液、注射用磷酸肌酸钠、小儿清热止咳颗粒等；资质到期品种1054个：注射用维布妥昔单抗、依洛硫酸酯酶α注射液、盐酸阿莫罗芬乳膏、糠酸氟替卡松维兰特罗吸入粉雾剂(Ⅱ) 、安立生坦片、拉西地平片、地夸磷索钠滴眼液、复方甘菊利多卡因凝胶、注射用艾塞那肽微球、比克恩丙诺片、索磷维伏片、恩曲他滨丙酚替诺福韦片(Ⅰ) 、注射用头孢硫脒、三七止血咀嚼片、聚维酮碘药膜、腹膜透析液(乳酸盐)(低钙) 、复方愈创木酚磺酸钾口服溶液、甲磺酸艾立布林注射液、瑞格列奈片、盐酸阿莫罗芬乳膏、硫酸沙丁胺醇吸入气雾剂、艾曲泊帕乙醇胺片、格隆溴铵吸入粉雾剂用胶囊、平衡盐溶液(供灌注用) 、注射用硫普罗宁、曲氟尿苷替匹嘧啶片、盐酸莫雷西嗪片等；

2022-09-05

·药明康德

胃溃疡治愈率可达91.4%！FDA批准新型胃酸抑制剂

Azurity Pharmaceuticals今日宣布美国FDA批准其口服悬浮液药品Konvomep用于治疗进行性良性胃溃疡（gastric ulcer）以及减少病危患者上肠胃道出血的风险。胃溃疡是在胃内部表层生疮的情形。最常见的致病原因是幽门螺杆菌（Helicobacter pylori）感染以及服用非甾体抗炎药（NSAID）造成胃酸分泌过多。患者会出现灼烧般胃痛、腹胀、心灼感、恶心与脂肪性食物可消化量降低等症状。病危患者，即那些于重症监护治疗病房（ICU）治疗的病患，由于生理上压力等原因，比一般人更容易出现因溃疡引起的上肠胃道出血现象。 Konvomep是一种由质子泵抑制剂（PPI）omeprazole与碳酸氢钠组合而成的悬浮液药品。Omeprazole能够通过对表达于胃粘膜中H/K-ATP酶（质子泵）系统的抑制，来减少胃酸的分泌。这种作用可抑制基础与刺激性胃酸分泌，无论其刺激来源为何，且抑制效果与所使用的药物剂量相关。这次Konvomep获得批准用于治疗进行性良性胃溃疡，主要是根据两项试验结果。在一多中心、双盲试验当中，服用每天一次40毫克omeprazole的病患（n=214）与安慰剂组（n=104）相较，在试验第8周时，患者胃溃疡治愈率分别为82.7%与48.1%（p<0.01）。而在另一项包含活性对照的多中心、双盲试验当中，服用每天一次40毫克omeprazole的病患（n=187）与一天两次150毫克ranitidine组（n=199）相较，患者胃溃疡治愈率分别为91.4%与78.4%（p<0.01）。此外，在另一项多中心、双盲、随机、非劣效性试验当中，共有359位病危成人患者入组。在经过平均6.8天（最长达14天）的治疗后，有3.9%使用40毫克omeprazole口服悬浮液患者（n=7/178）与5.5%使用静脉输注药物cimetidine患者（n=10/181）出现临床上显著上肠胃道出血现象，此结果显示此两种药品疗效相当。 “我们对于病患能够很快获得经FDA批准、这项常见质子泵抑制剂处方药物的口服液体配方感到高兴，”Azurity的首席执行官Richard Blackburn先生说道，“病患是我们优先考虑的对象。我们的目的是通过开发新的配方，为他们带来现有药物的好处。Konvomep尤其能够为那些对吞咽药锭或胶囊有困难的病患带来针对他们需要的治疗选项。” 参考资料：[1] AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension). Retrieved September 2, 2022 from https://azurity.com/azurity-pharmaceuticals-inc-announces-fda-approval-of-konvomep-omeprazole-and-sodium-bicarbonate-for-oral-suspension/[2] Prescribing Information- KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension). Retrieved September 2, 2022 from https://konvomep.com/wp-content/uploads/2022/09/konvomp-pi-word-final_08_2022.pdf[3] Peptic ulcer. Retrieved September 2, 2022 from https://www.mayoclinic.org/diseases-conditions/peptic-ulcer/symptoms-causes/syc-20354223[4] Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. Retrieved September 2, 2022 from https://www-bmj-com.libproxy1.nus.edu.sg/content/368/bmj.l6722.long 内容来源于网络，如有侵权，请联系删除。

免疫疗法

2019-11-26

·BioPortfolio

MHRA announces recall of 13 over-the-counter ranitidine medicines

Four companies are recalling batches of certain over-the-counter ranitidine medicines used to treat conditions such as stomach ulcers and heartburn. The post MHRA announces recall of 13 over-the-counter ranitidine medicines appeared first on European Pharmaceutical Review.

100 项与雷尼替丁枸橼酸铋相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05699	雷尼替丁枸橼酸铋	A02BA02	DBSALT001128

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
糜烂性食管炎	美国	GSK Plc	1998-03-23
胃食管反流	美国	GSK Plc	1998-03-23
Zollinger-Ellison综合征	美国	GSK Plc	1998-03-23
十二指肠溃疡	美国	GSK Plc	1996-01-01
胃溃疡	美国	GSK Plc	1996-01-01
螺杆菌感染	英国	GSK Plc	1995-09-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01896557 (CTgov)	临床4期	冠心病 \| 药物相互作用	92	clopidogrel+omeprazole (Omeprazole)	遞網餘淵齋膚選夢築廠(築鏇積範獵製艱醖膚獵) = 鹹鏇鑰衊壓壓簾膚鏇製淵淵壓遞淵膚鏇廠鹽顧 (衊選衊簾構衊鹽獵壓衊, 72.28) 更多	-	2016-05-23
				clopidogrel+Ranitidine (Ranitidine)	遞網餘淵齋膚選夢築廠(築鏇積範獵製艱醖膚獵) = 鹹鏇範齋繭獵鏇積艱衊淵淵壓遞淵膚鏇廠鹽顧 (衊選衊簾構衊鹽獵壓衊, 70.12) 更多